PMID- 23946770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 6
IP  - 1
DP  - 2013 Jul
TI  - HER2 gene amplification in esophageal squamous cell carcinoma is less than in 
      gastroesophageal junction and gastric adenocarcinoma.
PG  - 13-18
AB  - The aim of the present study was to detect the amplification of the human 
      epidermal growth factor receptor 2 (HER2) gene in esophageal squamous cell 
      carcinoma (ESCC), gastroesophageal junction adenocarcinoma (GEJAC) and gastric 
      cancer (GC), as well as to understand the pathological meaning of HER2 gene 
      amplification with regard to clinico-pathological parameters in these types of 
      cancer. HER2 gene amplification was evaluated by fluorescence in situ 
      hybridization (FISH) in surgically obtained specimens from 76 cases of ESCC, 50 
      of GEJAC and 48 of GC, as well as 21 specimens of tumor-adjacent normal 
      epithelium as a control group. The HER2 gene amplification rates in ESCC, GEJAC 
      and GC were 3.9 (3/76), 24.0 (12/50) and 18.8% (9/48), respectively. The rates of 
      HER2 gene amplification in GEJAC and GC were significantly higher compared with 
      ESCC (chi(2)=11.563, P<0.001 and chi(2)=7.375, P<0.007, respectively). HER2 gene 
      amplification was not detected in the normal esophageal or gastric mucosa 
      samples. In ESCC, HER2 gene amplification was correlated with the invasion of the 
      ESCC cells, vascular invasion and lymph node metastasis (chi(2)=4.789, 3.858 and 
      5.354, respectively; all P<0.05). However, in GEJAC and GC, no correlations were 
      observed between HER2 amplification and the gender, age, degree of 
      differentiation, invasion, vascular invasion and lymph node metastases of the 
      patients (all P>0.05). The rate of HER-2 gene amplification was low in ESCC, 
      although the amplification of HER-2 was correlated with tumor metastasis in these 
      patients. The rates of HER-2 gene amplification in GEJAC and GC were higher 
      compared with ESCC. Therefore, compared with ESCC, GEJAC may be more similar to 
      GC with regard to HER-2 gene amplification features.
FAU - Huang, Jun-Xing
AU  - Huang JX
AD  - Departments of Oncology, The People's Hospital of Taizhou, Taizhou Medical 
      School, Jiangsu and Nantong University, Taizhou, Jiangsu 225300, P.R. China.
FAU - Zhao, Kun
AU  - Zhao K
FAU - Lin, Mei
AU  - Lin M
FAU - Wang, Qi
AU  - Wang Q
FAU - Xiao, Wei
AU  - Xiao W
FAU - Lin, Mao-Song
AU  - Lin MS
FAU - Yu, Hong
AU  - Yu H
FAU - Chen, Ping
AU  - Chen P
FAU - Qian, Rong-Yu
AU  - Qian RY
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC3742794
OTO - NOTNLM
OT  - esophageal cancer
OT  - fluorescence in situ hybridization
OT  - gastric cancer
OT  - human epidermal growth factor receptor 2 gene
EDAT- 2013/08/16 06:00
MHDA- 2013/08/16 06:01
PMCR- 2013/05/15
CRDT- 2013/08/16 06:00
PHST- 2012/12/13 00:00 [received]
PHST- 2013/04/25 00:00 [accepted]
PHST- 2013/08/16 06:00 [entrez]
PHST- 2013/08/16 06:00 [pubmed]
PHST- 2013/08/16 06:01 [medline]
PHST- 2013/05/15 00:00 [pmc-release]
AID - ol-06-01-0013 [pii]
AID - 10.3892/ol.2013.1348 [doi]
PST - ppublish
SO  - Oncol Lett. 2013 Jul;6(1):13-18. doi: 10.3892/ol.2013.1348. Epub 2013 May 15.